![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/03/2892256/0/en/Celularity-Presents-Data-of-The-Effect-of-Its-T-Cell-Platform-on-Multiple-Hematological-And-Solid-Tumors-at-the-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/05/24/2888196/0/en/Celularity-Inc-Announces-Receipt-of-Nasdaq-Notice-Regarding-Late-Form-10-Q-Filing.html
https://www.globenewswire.com/news-release/2024/05/14/2881500/0/en/Celularity-Data-Published-in-Journal-for-ImmunoTherapy-of-Cancer-Reveals-Benefits-of-Placental-Circulating-T-Cells-for-CAR-T-Therapy.html
https://www.globenewswire.com/news-release/2024/04/22/2866807/0/en/Celularity-Inc-to-Host-Investor-and-Analyst-Research-Development-Day.html
https://www.globenewswire.com/news-release/2024/04/19/2866398/0/en/Celularity-Inc-Announces-Receipt-of-Nasdaq-Notice-Regarding-Late-Form-10-K-Filing.html
https://www.globenewswire.com/news-release/2024/04/18/2865850/0/en/Celularity-Abstract-Emerging-Technologies-for-the-Management-and-Protection-of-Tendon-Injuries-Decellularized-Placental-Biomaterials-Accepted-at-ORS-Tendon-Conference-2024.html
https://www.globenewswire.com/news-release/2024/04/15/2862735/0/en/Celularity-Announces-Net-Sales-Trending-Ahead-of-Expectations-for-First-Quarter-2024-Implements-Planned-2024-SG-A-Reductions-and-Manufacturing-Ramp-for-Advanced-Biomaterial-Product.html
https://www.globenewswire.com/news-release/2024/04/08/2859230/0/en/Celularity-to-Present-Data-Showing-Senescent-Cell-Elimination-by-Off-the-Shelf-Natural-Killer-Cells-Derived-from-Human-Placental-Cells.html
https://www.globenewswire.com/news-release/2024/03/26/2852421/0/en/Celularity-Receives-Healthcare-Common-Procedure-Coding-System-HCPCS-Q-Code-Approval-from-the-U-S-Centers-for-Medicare-Medicaid-Services-for-Biovance-3L.html
https://www.globenewswire.com/news-release/2024/03/20/2849426/0/en/Celularity-Submits-Request-to-U-S-FDA-for-Orphan-Drug-Designation-for-PDA-002-Asset-Treating-Facioscapulohumeral-Muscular-Dystrophy.html